Home > Insider Trading > Filing (0000950170-24-015479)

Filing Details

Accession Number:: 0000950170-24-015479
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-02-14 19:04:56
Reporting Period:: 2024-02-12

Accepted Time:: 2024-02-14 19:04:56
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1994702	Kyverna Therapeutics Inc.	KYTX	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1724489	Vida Ventures, Llc	40 Broad Street, Suite 201 Boston MA 02109	No	No	No	No
1855502	Vida Ventures Gp Iii, L.l.c.	40 Broad Street, Suite 201 Boston MA 02109	No	No	No	No
1855503	Vida Ventures Iii-A, L.p.	40 Broad Street, Suite 201 Boston MA 02109	No	No	No	No
1855504	Vida Ventures Iii, L.p.	40 Broad Street, Suite 201 Boston MA 02109	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-02-12	4,523,924	$0.00	4,523,924	No	4	C	Indirect	By Vida Ventures, LLC
Common Stock	Acquisiton	2024-02-12	252,553	$22.00	252,553	No	4	P	Indirect	By Vida Ventures III, L.P.
Common Stock	Acquisiton	2024-02-12	583	$22.00	583	No	4	P	Indirect	By Vida Ventures III-A, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Vida Ventures, LLC
No	4	P	Indirect	By Vida Ventures III, L.P.
No	4	P	Indirect	By Vida Ventures III-A, L.P.

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Redeemable Convertible Preferred Stock	Disposition	2024-02-12	4,401,771	$0.00	967,188	$0.00
Common Stock	Series A-2 Redeemable Convertible Preferred Stock	Disposition	2024-02-12	8,830,901	$0.00	1,940,388	$0.00
Common Stock	Series B Redeemable Convertible Preferred Stock	Disposition	2024-02-12	7,356,162	$0.00	1,616,348	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration.
The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any.
The shares of the Issuer's Common Stock are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
The shares of the Issuer's Common Stock are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.